JP2018531936A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018531936A5 JP2018531936A5 JP2018516772A JP2018516772A JP2018531936A5 JP 2018531936 A5 JP2018531936 A5 JP 2018531936A5 JP 2018516772 A JP2018516772 A JP 2018516772A JP 2018516772 A JP2018516772 A JP 2018516772A JP 2018531936 A5 JP2018531936 A5 JP 2018531936A5
- Authority
- JP
- Japan
- Prior art keywords
- level
- patient
- item
- reg3α
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 415
- 108091034117 Oligonucleotide Proteins 0.000 claims description 188
- 101700026522 SMAD7 Proteins 0.000 claims description 181
- 102000049873 Smad7 Human genes 0.000 claims description 181
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 181
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 181
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 128
- 230000007423 decrease Effects 0.000 claims description 116
- 108010002616 Interleukin-5 Proteins 0.000 claims description 84
- 102000003816 Interleukin-13 Human genes 0.000 claims description 83
- 108090000176 Interleukin-13 Proteins 0.000 claims description 83
- 102100024484 Codanin-1 Human genes 0.000 claims description 33
- 101000980888 Homo sapiens Codanin-1 Proteins 0.000 claims description 33
- 208000004998 Abdominal Pain Diseases 0.000 claims description 28
- 239000007788 liquid Substances 0.000 claims description 28
- 239000002773 nucleotide Substances 0.000 claims description 25
- 125000003729 nucleotide group Chemical group 0.000 claims description 25
- 206010012735 Diarrhoea Diseases 0.000 claims description 20
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 18
- 208000011231 Crohn disease Diseases 0.000 claims description 16
- 231100000682 maximum tolerated dose Toxicity 0.000 claims description 14
- LUCHPKXVUGJYGU-XLPZGREQSA-N 5-methyl-2'-deoxycytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 LUCHPKXVUGJYGU-XLPZGREQSA-N 0.000 claims description 10
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 10
- 238000002965 ELISA Methods 0.000 claims description 10
- 101000652166 Homo sapiens Mothers against decapentaplegic homolog 7 Proteins 0.000 claims description 10
- 108090001007 Interleukin-8 Proteins 0.000 claims description 10
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 10
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 10
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 10
- 238000004458 analytical method Methods 0.000 claims description 10
- 102000044356 human SMAD7 Human genes 0.000 claims description 10
- 239000003246 corticosteroid Substances 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 238000012544 monitoring process Methods 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 229960001334 corticosteroids Drugs 0.000 claims description 3
- 230000003247 decreasing effect Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims 58
- 102100036848 C-C motif chemokine 20 Human genes 0.000 claims 2
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 claims 2
- 101000853002 Homo sapiens Interleukin-25 Proteins 0.000 claims 2
- 101001128431 Homo sapiens Myeloid-derived growth factor Proteins 0.000 claims 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 1
- 108091058543 REG3 Proteins 0.000 claims 1
- 102100027336 Regenerating islet-derived protein 3-alpha Human genes 0.000 claims 1
- 102000000743 Interleukin-5 Human genes 0.000 description 82
- 229940100602 interleukin-5 Drugs 0.000 description 82
- 102000013691 Interleukin-17 Human genes 0.000 description 81
- 108050003558 Interleukin-17 Proteins 0.000 description 81
- 108010074051 C-Reactive Protein Proteins 0.000 description 9
- 102100032752 C-reactive protein Human genes 0.000 description 9
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 8
- 102000004890 Interleukin-8 Human genes 0.000 description 8
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 4
- 229960004909 aminosalicylic acid Drugs 0.000 description 4
- 239000003018 immunosuppressive agent Substances 0.000 description 4
- 229940124624 oral corticosteroid Drugs 0.000 description 4
- 229960005489 paracetamol Drugs 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 230000001861 immunosuppressant effect Effects 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 description 1
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 description 1
- 102000008080 Pancreatitis-Associated Proteins Human genes 0.000 description 1
- 108010074467 Pancreatitis-Associated Proteins Proteins 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562235556P | 2015-09-30 | 2015-09-30 | |
| US62/235,556 | 2015-09-30 | ||
| PCT/EP2016/073518 WO2017055611A2 (en) | 2015-09-30 | 2016-09-30 | Methods of using smad7 antisense oligonucleotides based on biomarker expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018531936A JP2018531936A (ja) | 2018-11-01 |
| JP2018531936A5 true JP2018531936A5 (enExample) | 2019-11-07 |
Family
ID=57113318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018516772A Pending JP2018531936A (ja) | 2015-09-30 | 2016-09-30 | バイオマーカー発現に基づいてｓｍａｄ７アンチセンスオリゴヌクレオチドを使用する方法 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP3355896A2 (enExample) |
| JP (1) | JP2018531936A (enExample) |
| CA (1) | CA3000569A1 (enExample) |
| WO (1) | WO2017055611A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20030149A1 (it) | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
| RS56049B1 (sr) | 2008-11-13 | 2017-09-29 | Nogra Pharma Ltd | Antisens kompozicije i postupci za pripremu i upotrebu istih |
| KR102099990B1 (ko) | 2011-09-15 | 2020-04-13 | 노그라 파마 리미티드 | 항-smad7 요법의 반응성을 모니터링하는 방법 |
| RU2667960C2 (ru) | 2012-04-18 | 2018-09-25 | Ногра Фарма Лимитед | Способы лечения диабета и/или улучшения выживания панкреатических островков после трансплантации |
| US10006029B2 (en) | 2013-03-15 | 2018-06-26 | Nogra Pharma Limited | Methods of treating colorectal cancer |
| CN106573065A (zh) | 2014-05-09 | 2017-04-19 | 诺格尔制药有限公司 | 用于治疗炎症性肠病的方法 |
| EP3207136A1 (en) | 2014-10-17 | 2017-08-23 | Nogra Pharma Limited | Methods and compositions for treating a subject with a smad7 antisense oligonucleotide |
| US11162097B2 (en) | 2016-02-23 | 2021-11-02 | Nogra Pharma Limited | Methods of treating intestinal fibrosis using SMAD7 inhibition |
| WO2019023439A1 (en) * | 2017-07-28 | 2019-01-31 | Celgene Corporation | PROCESS FOR THE PREPARATION OF OLIGONUCLEOTIDE COMPOUNDS |
| US20220267428A1 (en) * | 2018-10-10 | 2022-08-25 | The Board Of Trustees Of The Leland Stanford Junior University | BLOCKADE OF RGMb FOR TREATING INFLAMMATORY BOWEL DISEASE AND COLITIS |
| KR102824401B1 (ko) * | 2018-11-30 | 2025-06-25 | 아레나 파마슈티칼스, 인크. | S1p1 수용체와 관련된 병태의 치료 방법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060135610A1 (en) * | 2004-12-22 | 2006-06-22 | Bortz Jonathan D | Cardiovascular compositions |
| FI20075968A0 (fi) * | 2007-12-28 | 2007-12-28 | Licentia Oy | Menetelmä immunomodulaattorihoitojen tehokkuuden tarkkailemiseksi |
| JP2012507723A (ja) * | 2008-11-03 | 2012-03-29 | シェーリング コーポレイション | 炎症性腸疾患生物マーカーおよび関連治療方法 |
| RS56049B1 (sr) * | 2008-11-13 | 2017-09-29 | Nogra Pharma Ltd | Antisens kompozicije i postupci za pripremu i upotrebu istih |
| EP2702076A1 (en) * | 2011-04-29 | 2014-03-05 | Bristol-Myers Squibb Company | Ip-10 antibody dosage escalation regimens |
| KR102099990B1 (ko) * | 2011-09-15 | 2020-04-13 | 노그라 파마 리미티드 | 항-smad7 요법의 반응성을 모니터링하는 방법 |
-
2016
- 2016-09-30 WO PCT/EP2016/073518 patent/WO2017055611A2/en not_active Ceased
- 2016-09-30 EP EP16778306.7A patent/EP3355896A2/en not_active Withdrawn
- 2016-09-30 JP JP2018516772A patent/JP2018531936A/ja active Pending
- 2016-09-30 CA CA3000569A patent/CA3000569A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018531936A5 (enExample) | ||
| Corren | New targeted therapies for uncontrolled asthma | |
| Sabogal Piñeros et al. | Anti–IL-5 in mild asthma alters rhinovirus-induced macrophage, B-cell, and neutrophil responses (MATERIAL). A placebo-controlled, double-blind study | |
| Russell et al. | Pathogenesis of asthma: implications for precision medicine | |
| Tulic et al. | Amb a 1–immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response | |
| Pagnini et al. | Novel pharmacological therapy in inflammatory bowel diseases: beyond anti-tumor necrosis factor | |
| Kaur et al. | Systematic review of tofacitinib: a new drug for the management of rheumatoid arthritis | |
| Liu et al. | Type 2 cysteinyl leukotriene receptors drive IL-33–dependent type 2 immunopathology and aspirin sensitivity | |
| JP6306588B2 (ja) | Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法 | |
| Domingo | Omalizumab for severe asthma: efficacy beyond the atopic patient? | |
| EP3265493B1 (en) | Method of treating a localized fibrotic disorder using an il-33 antagonist | |
| CN112807427A (zh) | 一种抗-cxcl10抗体在制备用于治疗受试者中的炎性疾病的用途 | |
| JP2019507755A5 (enExample) | ||
| JP2020516289A (ja) | Ｉｌ３３及びｉｌ１ｒｌ１をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害 | |
| JP2017515828A (ja) | 関節リウマチのための治療 | |
| Kook et al. | Serum miR‐214 as a novel biomarker for ankylosing spondylitis | |
| Chang et al. | Regulation of ICAM‐1 expression in gingival fibroblasts infected with high‐glucose‐treated P. gingivalis | |
| Matera et al. | An overview of the preclinical discovery and development of tezepelumab for the treatment of asthma | |
| RU2020133768A (ru) | Способ лечения астмы или аллергического заболевания | |
| JP2019519544A5 (enExample) | ||
| AU2021279277A1 (en) | Treatment of cardiometabolic disease with inhibitors of type I interferon signalling | |
| WO2021243177A1 (en) | Markers and cellular antecedents of rheumatoid arthritis flares | |
| Albanna et al. | Clinical characteristics and outcome related to blood eosinophilic chronic obstructive pulmonary disease (COPD) patients | |
| Bell et al. | Biologic therapies in non-rheumatic diseases: lessons for rheumatologists? | |
| JP2019505598A5 (enExample) |